The SATURİSTA Device (SATURİSTA)
Development and Pilot Evaluation of an Artificial Intelligence-Assisted System for Automated Oxygen Flow Regulation: The Saturista Device
This study aims to evaluate the functional performance and feasibility of the Saturista system, a novel device designed for automated oxygen flow regulation based on continuous monitoring of oxygen saturation (SpO₂). The system integrates real-time physiological monitoring, wireless data transmission, and centralized visualization to support timely detection of oxygen desaturation and clinical decision-making.
A pilot feasibility study will be conducted in healthy volunteers using a scenario-based protocol, including baseline monitoring, controlled desaturation, probe disconnection, and signal recovery. The primary objective is to assess the system's ability to generate alarms in response to changes in SpO₂ and to display data in real time. Secondary objectives include evaluation of response time, signal management, and overall system stability.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
The Saturista system is a novel, integrated platform designed to support automated oxygen therapy management through continuous monitoring of oxygen saturation (SpO₂) and real-time decision support. The system combines pulse oximetry-based sensing, wireless data transmission, a cloud-based data infrastructure, and a web-based user interface within a distributed closed-loop control architecture.
In conventional clinical practice, oxygen therapy is typically adjusted manually based on intermittent assessment of oxygen saturation. This approach may delay recognition of physiological deterioration and timely intervention. The Saturista system addresses this limitation by enabling continuous monitoring, automated alarm generation, and centralized visualization of patient data at the nursing station.
The system consists of three main components: (i) a pulse oximetry-based monitoring module, (ii) an embedded device with wireless communication capabilities that regulates oxygen flow via a pneumatic valve mechanism, and (iii) a cloud-based software platform that processes physiological data and provides real-time visualization and alarm management.
This study is designed as a pilot feasibility study conducted in healthy volunteers to evaluate the technical and functional performance of the system. A scenario-based testing protocol will be applied, including baseline monitoring, controlled desaturation through short-duration breathing maneuvers, probe disconnection, and signal recovery. These scenarios simulate common clinical monitoring conditions and allow assessment of system responsiveness and reliability.
The primary outcome measures include the system's ability to detect decreases in SpO₂ and generate appropriate alarms, as well as its capacity to display physiological data in real time. Secondary outcomes include system response time, detection of signal loss, recovery performance, and overall operational stability.
The findings of this study are expected to provide preliminary evidence regarding the feasibility and functional performance of the Saturista system and to inform the design of future clinical studies in patient populations.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Luoghi di studio
-
-
-
Istanbul, Turchia (Türkiye)
- Istinye University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
The study population consists of healthy adult volunteers recruited for a pilot feasibility evaluation of the Saturista system. Participants are individuals without known respiratory or cardiovascular disease and with normal baseline oxygen saturation levels.
The purpose of selecting a healthy population is to assess the technical performance and functional reliability of the system under controlled conditions before clinical testing in patient populations. All participants will undergo a structured, scenario-based testing protocol, including baseline monitoring, controlled desaturation maneuvers within safe physiological limits, probe disconnection, and signal recovery.
This population allows for standardized assessment of the system's ability to monitor SpO₂, generate alarms, display real-time data, and manage signal-related events without the confounding effects of underlying clinical conditions.
Descrizione
Inclusion Criteria:
- Healthy adult volunteers aged 18 years or older
- Resting oxygen saturation (SpO₂) within the normal range at baseline
- Ability to understand the study procedures and provide written informed consent
- Willingness to participate in all planned testing scenarios
Exclusion Criteria:
- History of chronic respiratory disease, including asthma, chronic obstructive pulmonary disease, or interstitial lung disease
- Known cardiovascular disease or any condition that may affect oxygen saturation or hemodynamic stability
- Current respiratory symptoms, acute infection, or fever at the time of participation
- Anemia, peripheral circulatory disorders, or any condition that may interfere with pulse oximetry measurements
- Skin lesions, deformity, or injury at the intended probe placement site
- Pregnancy
- History of syncope, intolerance to short-duration breath-holding, or any condition that may increase risk during testing
- Inability or unwillingness to comply with study procedures
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
|---|
|
Healthy Adult Volunteers (Pilot Feasibility Cohort)
This cohort includes healthy adult volunteers participating in a pilot feasibility study to evaluate the functional performance of the Saturista system. Participants will undergo a structured, scenario-based testing protocol under controlled conditions. The protocol includes baseline monitoring, controlled desaturation through short-duration breathing maneuvers, probe disconnection, and signal recovery. The purpose of this cohort is to assess the system's ability to monitor oxygen saturation (SpO₂), generate alarms in response to predefined threshold changes, display data in real time, and manage signal interruption and recovery. No therapeutic intervention is applied, and all procedures are conducted within safe physiological limits under supervision. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Real-Time Data Display Performance
Lasso di tempo: Day 1, during multiple predefined simulation scenarios applied sequentially within a single testing session
|
Proportion of measurements successfully displayed on the user interface in real time during all testing scenarios.
|
Day 1, during multiple predefined simulation scenarios applied sequentially within a single testing session
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Alarm Response Time
Lasso di tempo: Day 1, during multiple predefined simulation scenarios applied sequentially within a single testing session
|
Time (in seconds) between a decrease in SpO₂ below the predefined threshold and activation of the system alarm.
|
Day 1, during multiple predefined simulation scenarios applied sequentially within a single testing session
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Display Delay
Lasso di tempo: Day 1, during multiple predefined simulation scenarios applied sequentially within a single testing session
|
Time (in seconds) between SpO₂ measurement and visualization on the user interface.
|
Day 1, during multiple predefined simulation scenarios applied sequentially within a single testing session
|
|
Signal Recovery Performance
Lasso di tempo: Day 1, during multiple predefined simulation scenarios applied sequentially within a single testing session
|
Proportion of scenarios in which the system successfully resumes valid data acquisition and terminates alarms after probe reconnection.
|
Day 1, during multiple predefined simulation scenarios applied sequentially within a single testing session
|
|
Technical Reliability
Lasso di tempo: Day 1, during multiple predefined simulation scenarios applied sequentially within a single testing session
|
Frequency of technical issues or system failures observed during testing sessions.
|
Day 1, during multiple predefined simulation scenarios applied sequentially within a single testing session
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Hansen EF, Hove JD, Bech CS, Jensen JS, Kallemose T, Vestbo J. Automated oxygen control with O2matic(R) during admission with exacerbation of COPD. Int J Chron Obstruct Pulmon Dis. 2018 Dec 14;13:3997-4003. doi: 10.2147/COPD.S183762. eCollection 2018.
- McMullan J, Hart KW, Barczak C, Lindsell CJ, Branson R. Supplemental Oxygen Requirements of Critically Injured Adults: An Observational Trial. Mil Med. 2016 Aug;181(8):767-72. doi: 10.7205/MILMED-D-15-00356.
- Douin DJ, Rice JD, Xiao M, Beaty L, Guo C, Withers C, Sullivan A, Anderson EL, Cheng AC, Banasiewicz MK, Semler MW, Lloyd BD, Maiga A, Gibbs KW, Stettler GR, Khan A, Sally MB, Wright FL, Aggarwal N, Bebarta VS, Ginde AA; SAVE-O2 AI Investigators. Statistical analysis plan for the Strategy to Avoid Excessive Oxygen using Autonomous Oxygen Titration Intervention (SAVE-O2 AI) trial: protocol. BMJ Open. 2026 Jan 28;16(1):e110739. doi: 10.1136/bmjopen-2025-110739.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- 25-134
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Ossigenoterapia
-
Tokat Gaziosmanpasa UniversityCompletatoEffetti della Pet Therapy sul sonno e sulla qualità della vitaTacchino
-
Dr Joanne CHIUReclutamentoRiarrangiamento genico ALK positivo | Carcinoma polmonare non a piccole cellule positivo per EGF-R | Mutazione attivante EGFR | Ncclc | Riarrangiamento del gene ROS1 | ROS1 NSCLC positivo - Reactive Oxygen Specie 1 Positivo carcinoma polmonare non a piccole celluleHong Kong